Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.

J Thorac Oncol 2019 May 31;14(5):793-801. Epub 2019 Jan 31.

Department of Medical Oncology, Yale School of Medicine, New Haven, Connecticut.

Introduction: In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1-expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.

Methods: Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ-Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.

Results: Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had "deteriorated" status and more had "improved" status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.

Conclusions: These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population.

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193009
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.01.016DOI Listing
May 2019
34 Reads

Publication Analysis

Top Keywords

quality life
12
ligand 1-expressing
8
compared docetaxel
8
death ligand
8
programmed death
8
patients treated
8
qlq-lc13 composite
8
docetaxel patients
8
time deterioration
8
pembrolizumab mg/kg
8
weeks docetaxel
8
proportion score
8
tumor proportion
8
docetaxel
8
symptom domains
8
deterioration qlq-lc13
8
composite endpoint
8
health-related quality
8
phase ii/iii
8
pembrolizumab
7

Altmetric Statistics

Similar Publications